A pdf file with the requested content has been emailed to you.
®BAVENCIO®
Avelumab for injection
Solution for Intravenous Infusion
- 20 mg/mL
Professed Standard Therapeutic Classification: Antineoplastic
BAVENCIO has been issued marketing authorization with conditions, pending the results of studies to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for BAVENCIO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site.
BAVENCIO is indicated for the treatment of:
- Metastatic Merkel cell carcinoma (MCC) in previously treated adults.
- Patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
